WINTON GROUP Ltd Makes New Investment in Boston Scientific Corporation $BSX

WINTON GROUP Ltd purchased a new stake in Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 147,742 shares of the medical equipment provider’s stock, valued at approximately $14,424,000. Boston Scientific makes up 0.5% of WINTON GROUP Ltd’s investment portfolio, making the stock its 29th largest holding.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank bought a new stake in Boston Scientific in the second quarter valued at about $2,089,937,000. Edgewood Management LLC bought a new position in Boston Scientific during the second quarter worth about $746,655,000. Parnassus Investments LLC lifted its stake in Boston Scientific by 42,978.9% during the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after purchasing an additional 6,868,459 shares during the period. Egerton Capital UK LLP boosted its holdings in Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after purchasing an additional 3,671,548 shares in the last quarter. Finally, Jennison Associates LLC grew its stake in shares of Boston Scientific by 133.5% in the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after purchasing an additional 2,823,744 shares during the period. 89.07% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Down 2.4%

Shares of BSX opened at $71.24 on Monday. The company has a market capitalization of $105.71 billion, a P/E ratio of 36.72, a PEG ratio of 1.00 and a beta of 0.69. Boston Scientific Corporation has a one year low of $70.75 and a one year high of $109.50. The business’s 50 day simple moving average is $85.03 and its 200-day simple moving average is $94.47. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BSX. Sanford C. Bernstein reissued an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a report on Friday, February 6th. Argus raised Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Wells Fargo & Company lowered their price target on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Mizuho dropped their price objective on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Finally, Truist Financial cut their price objective on Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $108.36.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.